MedVellum
MedVellum
Back to Library
Rheumatology
Internal Medicine

Vasculitis - Comprehensive

High EvidenceUpdated: 2025-12-25

On This Page

Red Flags

  • Signs of organ damage (kidney, lung, nervous system)
  • Rapid progression
  • Signs of critical organ involvement
  • Severe systemic symptoms
Overview

Vasculitis - Comprehensive

1. Clinical Overview

Summary

Vasculitis is inflammation of blood vessels, which can affect vessels of any size (small, medium, or large) and any organ system. Think of vasculitis as your immune system attacking your own blood vessels—this inflammation damages the vessel walls, causing them to narrow or block, leading to reduced blood flow to organs and tissues. Vasculitis can be primary (disease itself) or secondary (caused by another condition like infection, drugs, or other autoimmune diseases). There are many types of vasculitis, classified by the size of vessels affected and the organs involved (e.g., giant cell arteritis affects large vessels, granulomatosis with polyangiitis affects small vessels, polyarteritis nodosa affects medium vessels). The presentation varies widely depending on the type and organs affected, but common features include fever, weight loss, fatigue, and organ-specific symptoms (kidney: blood/protein in urine, lung: cough/breathlessness, skin: rash, nervous system: numbness/weakness). The key to management is recognizing the pattern (symptoms, signs, organ involvement), confirming the diagnosis (blood tests, imaging, biopsy), classifying the type (essential for treatment), and providing appropriate treatment (usually immunosuppression—steroids, sometimes other immunosuppressants). Early recognition and treatment are essential to prevent permanent organ damage.

Key Facts

  • Definition: Inflammation of blood vessels
  • Incidence: Rare to uncommon (varies by type, 1-50 per 100,000)
  • Mortality: Varies by type (5-30% if untreated, lower with treatment)
  • Peak age: Varies by type (some in young adults, some in older adults)
  • Critical feature: Multi-system involvement, inflammation of vessels
  • Key investigation: Clinical assessment, blood tests (ANCA, etc.), imaging, biopsy
  • First-line treatment: Immunosuppression (steroids, sometimes other agents)

Clinical Pearls

"Think multi-system" — Vasculitis usually affects multiple organ systems. If you see involvement of multiple systems (kidney + lung + skin, etc.), think vasculitis.

"ANCA is helpful but not diagnostic" — ANCA (anti-neutrophil cytoplasmic antibodies) is helpful for some types (granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis), but not all vasculitis is ANCA-positive. Don't rely on ANCA alone.

"Biopsy is often needed" — Biopsy of affected tissue (skin, kidney, lung, etc.) is often needed to confirm the diagnosis and classify the type. Don't skip this if diagnosis is uncertain.

"Type matters for treatment" — Different types of vasculitis need different treatments. Classifying the type is essential for appropriate treatment.

Why This Matters Clinically

Vasculitis is a serious condition that can cause permanent organ damage if not recognized and treated early. Early recognition (especially multi-system involvement), proper classification, and appropriate immunosuppressive treatment are essential. This is a condition that rheumatologists, nephrologists, and other specialists manage, and prompt treatment prevents organ damage.


2. Epidemiology

Incidence & Prevalence

  • Overall: Rare to uncommon (varies by type)
  • Giant cell arteritis: Most common large vessel (10-20 per 100,000)
  • Granulomatosis with polyangiitis: 2-5 per 100,000
  • Trend: Stable (rare conditions)
  • Peak age: Varies by type

Demographics

FactorDetails
AgeVaries by type (GCA = older, GPA = middle-aged)
SexVaries by type (some female-predominant, some male)
EthnicitySome types more common in certain populations
GeographyNo significant variation
SettingRheumatology, nephrology, internal medicine clinics

Risk Factors

Non-Modifiable:

  • Age (varies by type)
  • Sex (varies by type)
  • Genetics (some types)

Modifiable:

Risk FactorRelative RiskMechanism
Smoking2-3xSome types (GPA)
Infection2-3xCan trigger or cause secondary
Drugs2-3xCan cause secondary

Common Types

TypeVessel SizeFrequencyTypical Patient
Giant cell arteritisLargeMost common large vesselOlder adults, female
Granulomatosis with polyangiitisSmall2-5 per 100,000Middle-aged
Microscopic polyangiitisSmall1-3 per 100,000Middle-aged
Eosinophilic granulomatosis with polyangiitisSmallRareMiddle-aged
Polyarteritis nodosaMediumRareMiddle-aged
OtherVariousRareVarious

3. Pathophysiology

The Inflammation Mechanism

Step 1: Immune Dysregulation

  • Autoimmune: Immune system attacks own vessels
  • Trigger: May be triggered (infection, drugs, unknown)
  • Result: Immune activation

Step 2: Vessel Inflammation

  • Inflammation: Vessels become inflamed
  • Damage: Vessel walls damaged
  • Result: Vessel damage

Step 3: Vessel Narrowing/Blockage

  • Narrowing: Vessels narrow (stenosis)
  • Blockage: Vessels block (occlusion)
  • Result: Reduced blood flow

Step 4: Organ Damage

  • Ischemia: Organs don't get enough blood
  • Infarction: Tissue death
  • Dysfunction: Organ dysfunction
  • Result: Organ damage

Step 5: Clinical Manifestation

  • Symptoms: Organ-specific symptoms
  • Signs: Organ-specific signs
  • Result: Clinical presentation

Classification by Vessel Size

Vessel SizeTypesClinical Features
Large vesselGiant cell arteritis, Takayasu arteritisHeadache, claudication, vision loss
Medium vesselPolyarteritis nodosa, Kawasaki diseaseSkin, nerves, gut
Small vesselGPA, MPA, EGPA, IgA vasculitisKidney, lung, skin

Anatomical Considerations

Organ Systems Affected:

  • Kidney: Glomerulonephritis, renal failure
  • Lung: Pulmonary hemorrhage, nodules
  • Skin: Rash, ulcers
  • Nervous system: Neuropathy, stroke
  • Joints: Arthritis
  • Eyes: Scleritis, uveitis
  • GI tract: Ischemia, bleeding

Why Different Patterns:

  • Vessel size: Determines which organs affected
  • Type: Each type has characteristic pattern

4. Clinical Presentation

Symptoms: The Patient's Story

Typical Presentation (Systemic):

Organ-Specific Symptoms:

History:

Signs: What You See

Vital Signs (May Be Abnormal):

SignFindingSignificance
TemperatureMay be elevated (low-grade fever)Inflammation
Heart rateUsually normalUsually normal
Blood pressureMay be high (if kidney affected)Hypertension
Respiratory rateMay be high (if lung affected)Respiratory distress

General Appearance:

Organ-Specific Signs:

SystemSigns
KidneyHypertension, edema, signs of renal failure
LungCrackles, signs of respiratory distress
SkinRash, ulcers, nodules, purpura
Nervous systemNeuropathy, weakness, stroke signs
JointsSwelling, tenderness
EyesRedness, vision loss
GI tractAbdominal tenderness, signs of ischemia

Red Flags

[!CAUTION] Red Flags — Immediate Escalation Required:

  • Signs of organ damage (kidney, lung, nervous system) — Needs urgent assessment, may need urgent treatment
  • Rapid progression — Needs urgent assessment
  • Signs of critical organ involvement — Needs urgent treatment
  • Severe systemic symptoms — Needs urgent assessment

Fever
Low-grade fever
Weight loss
Unintentional weight loss
Fatigue
Severe fatigue
Malaise
General feeling unwell
5. Clinical Examination

Structured Approach: ABCDE

A - Airway

  • Assessment: Usually patent
  • Action: Secure if compromised

B - Breathing

  • Look: May have respiratory distress (if lung affected)
  • Listen: May have crackles (if lung affected)
  • Measure: SpO2 (may be low if lung affected)
  • Action: Support if needed

C - Circulation

  • Look: May have signs of organ damage
  • Feel: Pulse (usually normal), BP (may be high if kidney affected)
  • Listen: Heart sounds (usually normal)
  • Measure: BP (may be high), HR
  • Action: Monitor if organ damage

D - Disability

  • Assessment: Neurological status (may have neuropathy, stroke)
  • Action: Assess if neurological involvement

E - Exposure

  • Look: Full examination, look for multi-system involvement
  • Feel: Skin, joints, assess organs
  • Action: Complete examination

Specific Examination Findings

Multi-System Examination:

  • Kidney: Check BP, edema, signs of renal failure
  • Lung: Auscultate, check for respiratory distress
  • Skin: Look for rash, ulcers, nodules, purpura
  • Nervous system: Check for neuropathy, weakness, stroke signs
  • Joints: Check for swelling, tenderness
  • Eyes: Check for redness, vision
  • GI tract: Check for tenderness, signs of ischemia

Special Tests

TestTechniquePositive FindingClinical Use
ANCABlood testMay be positiveSome types (GPA, MPA, EGPA)
BiopsyTissue biopsyVessel inflammationDiagnostic
UrinalysisUrine testBlood, proteinKidney involvement

6. Investigations

First-Line (Bedside) - Do Immediately

1. Clinical Assessment (Most Important)

  • History: Multi-system symptoms
  • Examination: Multi-system signs
  • Action: High suspicion if multi-system

2. Blood Tests (Essential)

  • FBC: May show anemia, elevated white cells
  • CRP, ESR: Usually elevated (inflammation)
  • ANCA: If small vessel suspected
  • Action: Supports diagnosis

Laboratory Tests

TestExpected FindingPurpose
Full Blood CountMay show anemia, elevated white cellsInflammation
CRPElevatedInflammation
ESRElevatedInflammation
ANCAMay be positive (GPA, MPA, EGPA)Some types
UrinalysisBlood, protein (if kidney affected)Kidney involvement
Renal functionMay be impaired (if kidney affected)Kidney involvement

Imaging

CT/MRI (If Needed):

IndicationFindingClinical Note
Lung involvementNodules, hemorrhageIf lung affected
Vessel imagingVessel narrowing, inflammationIf large/medium vessel

Biopsy (Essential for Diagnosis):

IndicationFindingClinical Note
Affected tissueVessel inflammationDiagnostic

Diagnostic Criteria

Clinical Diagnosis:

  • Multi-system involvement + signs of inflammation + biopsy showing vasculitis = Vasculitis

Type Classification:

  • Vessel size: Large, medium, or small
  • ANCA: Positive or negative
  • Organ pattern: Which organs affected
  • Biopsy: Specific features

Severity Assessment:

  • Mild: Minimal organ involvement
  • Moderate: Significant organ involvement
  • Severe: Critical organ involvement

7. Management

Management Algorithm

        SUSPECTED VASCULITIS
    (Multi-system involvement + signs of inflammation)
                    ↓
┌─────────────────────────────────────────────────┐
│         CLINICAL ASSESSMENT                      │
│  • History (multi-system symptoms)               │
│  • Examination (multi-system signs)              │
│  • High suspicion if multi-system                 │
└─────────────────────────────────────────────────┘
                    ↓
┌─────────────────────────────────────────────────┐
│         INVESTIGATIONS                           │
│  • Blood tests (FBC, CRP, ESR, ANCA)              │
│  • Urinalysis (if kidney suspected)                │
│  • Imaging (if needed)                            │
│  • Biopsy (essential for diagnosis)                │
└─────────────────────────────────────────────────┘
                    ↓
┌─────────────────────────────────────────────────┐
│         CLASSIFY TYPE                            │
│  • Vessel size (large, medium, small)              │
│  • ANCA status                                    │
│  • Organ pattern                                   │
│  • Biopsy features                                 │
└─────────────────────────────────────────────────┘
                    ↓
┌─────────────────────────────────────────────────┐
│         TREATMENT                                │
├─────────────────────────────────────────────────┤
│  LARGE VESSEL (GCA, Takayasu)                    │
│  → High-dose steroids                             │
│  → May need other immunosuppressants               │
│                                                  │
│  SMALL VESSEL (GPA, MPA, EGPA)                   │
│  → High-dose steroids + cyclophosphamide or rituximab │
│  → Induction then maintenance                     │
│                                                  │
│  MEDIUM VESSEL (PAN)                             │
│  → High-dose steroids + cyclophosphamide          │
│                                                  │
│  OTHER                                           │
│  → As appropriate for type                         │
└─────────────────────────────────────────────────┘
                    ↓
┌─────────────────────────────────────────────────┐
│         MONITOR & FOLLOW-UP                       │
│  • Monitor organ function                         │
│  • Monitor disease activity                       │
│  • Adjust treatment as needed                      │
│  • Long-term management                            │
└─────────────────────────────────────────────────┘

Acute/Emergency Management - The First Hour

Immediate Actions (Do Simultaneously):

  1. Clinical Assessment

    • History: Multi-system symptoms
    • Examination: Multi-system signs
    • Action: High suspicion if multi-system
  2. Blood Tests (Urgent)

    • FBC, CRP, ESR: Assess inflammation
    • ANCA: If small vessel suspected
    • Urinalysis: If kidney suspected
    • Action: Supports diagnosis
  3. Assess Organ Function

    • Kidney: Check renal function
    • Lung: Check respiratory function
    • Other: As appropriate
    • Action: Assess severity
  4. Specialist Consultation

    • Rheumatology: Essential
    • Other specialists: As needed (nephrology, etc.)
    • Action: Don't delay
  5. Biopsy (If Needed)

    • Affected tissue: Biopsy for diagnosis
    • Action: Essential for diagnosis

Medical Management

Immunosuppression (Essential):

DrugDoseRouteDurationNotes
Prednisolone1mg/kg/day (max 60-80mg)POInduction then taperFirst-line
CyclophosphamideAs appropriatePO/IVInductionFor severe (GPA, MPA, PAN)
RituximabAs appropriateIVInductionAlternative to cyclophosphamide (GPA, MPA)
MethotrexateAs appropriatePO/SCMaintenanceFor maintenance
AzathioprineAs appropriatePOMaintenanceFor maintenance

Treatment by Type:

  • GCA: High-dose steroids, may need methotrexate
  • GPA/MPA: Steroids + cyclophosphamide or rituximab
  • EGPA: Steroids, may need other agents
  • PAN: Steroids + cyclophosphamide

Disposition

Admit to Hospital If:

  • Severe: Critical organ involvement
  • Needs IV treatment: If IV immunosuppression needed
  • Monitoring: Needs close monitoring

Outpatient Management:

  • Mild-moderate: Can be managed outpatient
  • Regular follow-up: Monitor disease activity

Discharge Criteria:

  • Stable: No critical organ involvement
  • Treatment started: Treatment initiated
  • Clear plan: For continued treatment, follow-up

Follow-Up:

  • Regular: Monitor disease activity, organ function
  • Long-term: Ongoing management
  • Adjust treatment: As needed

8. Complications

Immediate (Days-Weeks)

ComplicationIncidencePresentationManagement
Organ damage20-30%Kidney, lung, nervous system damageImmunosuppression, organ support
Renal failure10-20%If kidney affectedImmunosuppression, may need dialysis
Pulmonary hemorrhage5-10%If lung affectedUrgent immunosuppression, supportive care
Death5-30% (if untreated)If severe, untreatedPrevention through early treatment

Organ Damage:

  • Mechanism: Ischemia from vessel damage
  • Management: Immunosuppression, organ support
  • Prevention: Early treatment

Early (Weeks-Months)

1. Usually Improves with Treatment (70-80%)

  • Mechanism: Most respond to immunosuppression
  • Management: Continue treatment
  • Prevention: Early treatment

2. Persistent Organ Damage (20-30%)

  • Mechanism: Permanent damage from ischemia
  • Management: Ongoing management, may need organ replacement
  • Prevention: Early treatment

Late (Months-Years)

1. Relapse (30-50%)

  • Mechanism: Disease returns
  • Management: Re-treat, may need long-term immunosuppression
  • Prevention: Maintenance treatment

2. Chronic Organ Damage (20-30%)

  • Mechanism: Permanent damage
  • Management: Ongoing management
  • Prevention: Early treatment

9. Prognosis & Outcomes

Natural History (Without Treatment)

Untreated Vasculitis:

  • High mortality: 5-30% mortality (varies by type)
  • Organ damage: Almost certain
  • Poor outcomes: If not treated

Outcomes with Treatment

VariableOutcomeNotes
Remission70-80%Most achieve remission with treatment
Mortality5-15%Lower with treatment
Relapse30-50%May relapse
Organ damage20-30%May have permanent damage

Factors Affecting Outcomes:

Good Prognosis:

  • Early treatment: Better outcomes
  • No organ damage: Better outcomes
  • Type: Some types better prognosis
  • Good response: Better outcomes

Poor Prognosis:

  • Delayed treatment: Higher mortality, more organ damage
  • Organ damage: Worse outcomes
  • Type: Some types worse prognosis
  • Poor response: Worse outcomes

Prognostic Factors

FactorImpact on PrognosisEvidence Level
Early treatmentBetter outcomesHigh
Organ damageDamage = worseHigh
TypeSome types worseModerate
Response to treatmentGood response = betterModerate

10. Evidence & Guidelines

Key Guidelines

1. EULAR Guidelines (2016) — EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. European League Against Rheumatism

Key Recommendations:

  • Early recognition
  • Appropriate immunosuppression
  • Evidence Level: 1A

2. ACR Guidelines (2021) — American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody–associated vasculitis. American College of Rheumatology

Key Recommendations:

  • Similar to EULAR
  • Evidence Level: 1A

Landmark Trials

Multiple studies on immunosuppressive treatment, outcomes.

Evidence Strength

InterventionLevelKey EvidenceClinical Recommendation
Immunosuppression1AMultiple RCTsEssential
Biopsy for diagnosis1AMultiple studiesEssential

11. Patient/Layperson Explanation

What is Vasculitis?

Vasculitis is inflammation of blood vessels, which can affect vessels of any size and any organ system. Think of vasculitis as your immune system attacking your own blood vessels—this inflammation damages the vessel walls, causing them to narrow or block, leading to reduced blood flow to organs and tissues.

In simple terms: Your blood vessels have become inflamed, which can affect blood flow to different parts of your body. This is serious and needs treatment, but with proper treatment, most people do well.

Why does it matter?

Vasculitis is a serious condition that can cause permanent organ damage if not recognized and treated early. Early recognition and appropriate immunosuppressive treatment are essential. The good news? With proper treatment, most people achieve remission and do well.

Think of it like this: It's like your blood vessels becoming inflamed—this can affect blood flow to your organs, but with the right treatment, the inflammation can be controlled.

How is it treated?

1. Diagnosis:

  • Assessment: Your doctor will assess you to see which organs are affected
  • Tests: You'll have blood tests, urine tests, and sometimes a biopsy (small sample of tissue)
  • Why: To confirm the diagnosis and see which type of vasculitis you have

2. Treatment:

  • Immunosuppression: You'll get medicines to suppress your immune system (usually steroids, sometimes other medicines)
  • Why: To stop your immune system from attacking your blood vessels
  • Duration: Usually starts with high doses, then gradually reduced

3. Monitoring:

  • Regular check-ups: You'll have regular check-ups to monitor your disease and organ function
  • Adjust treatment: Your doctor will adjust your treatment as needed
  • Why: To keep the disease under control and prevent organ damage

The goal: Control the inflammation, prevent organ damage, and help you achieve remission.

What to expect

Recovery:

  • Treatment: Usually starts with high doses of medicines, then gradually reduced
  • Remission: Most people achieve remission (disease under control) within months
  • Relapse: Some people may have relapses (disease returns), which can be treated

After Treatment:

  • Medicines: You'll need to take medicines long-term (usually)
  • Monitoring: Regular monitoring of your disease and organ function
  • Lifestyle: Usually can live normally, but need to take medicines and have regular check-ups

Recovery Time:

  • Remission: Usually within months
  • Long-term: Ongoing management

When to seek help

See your doctor if:

  • You have symptoms that affect multiple systems (kidney, lung, skin, etc.)
  • You have unexplained fever, weight loss, or fatigue
  • You have symptoms that concern you
  • You have a known diagnosis of vasculitis and develop new symptoms

Call 999 (or your emergency number) immediately if:

  • You have severe symptoms (difficulty breathing, severe pain, etc.)
  • You feel very unwell
  • You have symptoms that concern you

Remember: If you have symptoms that affect multiple systems, especially if you have unexplained fever, weight loss, or fatigue, see your doctor. Vasculitis is serious, but with proper treatment, most people do well. Also, if you have a known diagnosis of vasculitis and develop new symptoms, see your doctor—this may indicate a relapse or complication.


12. References

Primary Guidelines

  1. Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583-1594. PMID: 27338776

  2. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366-1383. PMID: 34235894

Key Trials

  1. Multiple studies on immunosuppressive treatment, outcomes.

Further Resources

  • EULAR Guidelines: European League Against Rheumatism
  • ACR Guidelines: American College of Rheumatology

Last Reviewed: 2025-12-25 | MedVellum Editorial Team


Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists. This information is not a substitute for professional medical advice, diagnosis, or treatment.


13. Deep Dive: ANCA Pathogenesis (NETosis)

"The Trap that Backfires."

  • ANCA (Anti-Neutrophil Cytoplasmic Antibody) is not just a marker; it drives the disease.
  • Mechanism:
    1. Priming: Infection causes cytokines (TNF) to prime neutrophils, moving antigens (MPO/PR3) to the cell surface.
    2. Binding: ANCA antibodies bind to these antigens.
    3. Activation: This activates the neutrophils inappropriately.
    4. NETosis: Neutrophils release Neutrophil Extracellular Traps (NETs) - webs of DNA and enzymes meant to catch bacteria. In vasculitis, these NETs damage the delicate endothelial lining of capillaries (especially in the kidney).
  • Result: Necrotizing inflammation of small vessels (Pauci-immune).

14. Surgical Atlas: Biopsy Techniques

"Tissue is the Issue."

1. Renal Biopsy (Gold Standard for Renal Vasculitis)

  • Indication: Active urinary sediment (blood/protein) + rising creatinine.
  • Technique: Percutaneous ultrasound-guided core biopsy (Left kidney lower pole).
  • Findings:
    • Crescentic Glomerulonephritis: Rupture of Bowman's capsule with proliferation of parietal cells (Crescents).
    • Pauci-immune: Little staining for antibody/complement (distinguishes from Lupus).

2. Lung Biopsy

  • Indication: Pulmonary nodules/infiltrates without renal signs.
  • Technique:
    • Trans-bronchial: Low yield.
    • VATS (Video Assisted Thoracoscopic Surgery): Gold standard. Wedge resection.
  • Findings (GPA): Granulomatous inflammation + Necrosis + Vasculitis.

3. Skin Biopsy

  • Indication: Purpura.
  • Technique: Punch biopsy (4-5mm). Feature: Leukocytoclastic Vasculitis (broken white cells).

15. Technical Appendix: Vasculitis Mimics

"It looks like Vasculitis, but isn't." Treating these with steroids can be fatal.

  1. Infective Endocarditis:
    • Features: Fever, Murmur, Splinter haemorrhages, Glomerulonephritis (Immune complex).
    • Testing: Multiple sets of blood cultures + Echo. Rule #1: Exclude IE before diagnosing Vasculitis.
  2. Cholesterol Emboli:
    • Features: "Blue Toe Syndrome", Renal failure after angiogram.
    • Clue: Livedo reticularis + Hx of vascular procedure.
  3. Antiphospholipid Syndrome:
    • Features: Clots + Livedo. (Thrombosis, not inflammation).
  4. Cocaine/Levamisole:
    • Features: "Cocaine nose" (septal perforation) mimics GPA. Can cause positive ANCA.

16. Advanced Quiz (The "Gold" Level)

Q1: Which vasculitis is associated with Hepatitis B? A: Polyarteritis Nodosa (PAN). (Classic association).

Q2: What is the specific ANCA pattern for GPA vs MPA? A:

  • GPA (Wegener's) = c-ANCA (PR3).
  • MPA = p-ANCA (MPO).
  • (Note: Overlap exists).

Q3: What is "Pauci-immune"? A: "Few antibodies". On renal biopsy immunofluorescence, there is NO glowing green IgG/C3. This proves it is ANCA vasculitis, not Lupus (Full House) or Goodpasture's (Linear).

Q4: A patient on Cyclophosphamide develops blood in urine 5 years later. Diagnosis? A: Bladder Cancer (Transitional Cell Carcinoma). A major long-term risk of Cyclophosphamide.

Q5: Treatment for Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss)? A: Steroids are often sufficient for mild disease. Mepolizumab (Anti-IL5) is the new game-changer for the asthmatic component.


(End of Comprehensive Expansion)

Last updated: 2025-12-25

At a Glance

EvidenceHigh
Last Updated2025-12-25

Red Flags

  • Signs of organ damage (kidney, lung, nervous system)
  • Rapid progression
  • Signs of critical organ involvement
  • Severe systemic symptoms

Clinical Pearls

  • **"Think multi-system"** — Vasculitis usually affects multiple organ systems. If you see involvement of multiple systems (kidney + lung + skin, etc.), think vasculitis.
  • **"Biopsy is often needed"** — Biopsy of affected tissue (skin, kidney, lung, etc.) is often needed to confirm the diagnosis and classify the type. Don't skip this if diagnosis is uncertain.
  • **"Type matters for treatment"** — Different types of vasculitis need different treatments. Classifying the type is essential for appropriate treatment.
  • **Red Flags — Immediate Escalation Required:**
  • - **Signs of organ damage (kidney, lung, nervous system)** — Needs urgent assessment, may need urgent treatment

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines